We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Imara Inc (IMRA) USD0.001

Sell:$1.34 Buy:$1.35 Change: $0.03 (2.17%)
Market closed |  Prices as at close on 27 January 2022 | Switch to live prices |
Sell:$1.34
Buy:$1.35
Change: $0.03 (2.17%)
Market closed |  Prices as at close on 27 January 2022 | Switch to live prices |
Sell:$1.34
Buy:$1.35
Change: $0.03 (2.17%)
Market closed |  Prices as at close on 27 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Imara, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing novel therapeutics to treat rare inherited genetic disorders of hemoglobin. The Company’s product pipeline includes IMR-687 (tovinontrine). IMR-687 is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease (SCD and beta-thalassemi. IMR-687 is a selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9), that has a multimodal mechanism of action that acts primarily on red blood cells (RBCs) and has the potential to act on white blood cells (WBCs), adhesion mediators and other cell types. PDE9 decreases cyclic guanosine monophosphate (cGMP), an active signaling molecule. The Company is conducting Phase II b clinical trials of IMR-68.

Contact details

Address:
116 HUNTINGTON AVENUE, 6TH FLOOR
BOSTON
02116
United States
Telephone:
+1 (617) 2062020
Website:
https://imaratx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IMRA
ISIN:
US45249V1070
Market cap:
$39.41 million
Shares in issue:
26.28 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Rahul Ballal
    President, Chief Executive Officer, Director
  • Michael Gray
    Chief Financial Officer, Chief Operating Officer
  • Kenneth Attie
    Senior Vice President, Chief Medical Officer
  • Lynette Hopkinson
    Senior Vice President - Regulatory

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.